Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 30
- Registration Number
- NCT02542657
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 74
- Registration Number
- NCT02462525
- Locations
- 🇺🇸
Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States
🇺🇸Mount Sinai Medical Center /ID# 133569, New York, New York, United States
🇺🇸The University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT02431208
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
🇺🇸Emory Univ Winship Cancer Inst, Atlanta, Georgia, United States
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT02415153
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸National Cancer Institute, Rockville, Maryland, United States
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 124
- Registration Number
- NCT02406222
- Locations
- 🇬🇧
Beatson Oncology Centre, Glasgow, United Kingdom
🇬🇧New Cross Hospital, Wolverhampton, United Kingdom
🇬🇧Royal Sussex County Hospital, Brighton, United Kingdom
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 85
- Registration Number
- NCT02400242
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸University of Miami Medical Center, Miami, Florida, United States
🇺🇸Local Institution - 104, Boston, Massachusetts, United States
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 45
- Registration Number
- NCT02294357
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Blood & Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Ashraf Badros
- Target Recruit Count
- 48
- Registration Number
- NCT02289222
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 9
- Registration Number
- NCT02287558
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.